Physician profile
Gregor Rodriguez
NPI 1215433966
$1,975.10
in general payments reported to CMS, 2019-2025
28 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $123 · 2024: $165 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $260.60 | 2025 | |
| Merck Sharp & Dohme LLC | $184.39 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $169.81 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $166.91 | 2023-2025 | Calquence, Imfinzi |
| Celgene Corporation | $115.50 | 2025 | Opdualag, Reblozyl |
| Janssen Biotech, INC. | $114.41 | 2024-2025 | Rybrevant, Tecvayli, Darzalex |
| Gilead Sciences, INC. | $108.02 | 2025 | Trodelvy |
| Daiichi Sankyo INC. | $93.97 | 2025 | Enhertu, Datroway |
| Regeneron Healthcare Solutions, INC. | $82.18 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $74.00 | 2025 | |
| Genzyme Corporation | $57.02 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $57.02 | 2024-2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $56.82 | 2025 | Fruzaqla, Ninlaro |
| Array Biopharma INC | $56.38 | 2025 | Mektovi, Lorbrena, Braftovi |
| Bayer Healthcare Pharmaceuticals INC. | $54.44 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $42.60 | 2024-2025 | Orserdu |
| Janssen Scientific Affairs, LLC | $37.50 | 2025 | Carvykti, Darzalex, Tecvayli |
| Sobi, INC | $35.68 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $29.31 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $29.12 | 2025 | Onivyde |
| Beigene USA, INC. | $25.51 | 2025 | Brukinsa |
| Astellas Pharma US INC | $20.02 | 2025 | Xospata |
| Genentech USA, INC. | $19.98 | 2025 | Lunsumio, Polivy, Tecentriq |
| Glaxosmithkline, LLC. | $19.18 | 2025 | Ojjaara |
| Sumitomo Pharma America, INC. | $18.62 | 2025 | Orgovyx |
| Exelixis INC. | $18.41 | 2025 | Cabometyx |
| Incyte Corporation | $18.32 | 2025 | Jakafi, Niktimvo |
| Iovance Biotherapeutics, INC. | $9.38 | 2024 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregor Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.